Henning Glerup

Henning Glerup

Auto-generated profile, based on publicly available information

Henning Glerup

University Research Clinic for Innovative Patient Pathways, Silkeborg Regional Hospital, Silkeborg, Denmark

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2000 in Calcified Tissue International
Verified
Journal Article
Closed access
PDF file
HGH. Glerup
H. Glerup
KMK. Mikkelsen
K. Mikkelsen
LPL. Poulsen
L. Poulsen
EHE. Hass
E. Hass
SOS. Overbeck
S. Overbeck
EEE. F. Eriksen
E. F. Eriksen

1 May 2009 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
Christian WejseChristian Wejse
Christian Wejse
VGVictor F. Gomes
Victor F. Gomes
PRPaulo Rabna
Paulo Rabna
PGPer Gustafson
Per Gustafson
PAPeter Aaby
Peter Aaby
MSMorten Sodemann
Morten Sodemann
Rationale: Vitamin D has been shown to be involved in the host immune response toward Mycobacterium tuberculosis. Objectives: To test whether vitamin D supplementation of patients with tuberculosis (TB) improved clinical outcome and reduced mortality. Methods: We conducted a randomized, double-blind, placebo-controlled trial in TB clinics at a demographic surveillance site in Guinea-Bissau. We included 365 adult patients with TB starting antituberculosis treatment; 281 completed the 12-month follow-up. The intervention was 100,000 IU of cholecalciferol or placebo at inclusion and again 5 and 8 months after the start of treatment. Measurements and Main Results: The primary outcome was reduction in a clinical severity score (TBscore) for all patients with pulmonary TB. The secondary outcome was 12-month mortality. No serious adverse effects were reported; mild hypercalcemia was rare and present in both arms. Reduction in TBscore and sputum smear conversion rates did not differ among patients treated with vitamin D or placebo. Overall mortality was 15% (54 of 365) at 1 year of follow-up and similar in both arms (30 of 187 for vitamin D treated and 24 of 178 for placebo; relative risk, 1.19 [0.58–1.95]). HIV infection was seen in 36% (131 of 359): 21% (76 of 359) HIV-1, 10% (36 of 359) HIV-2, and 5% (19 of 357) HIV-1+2. Conclusions: Vitamin D does not improve clinical outcome among patients with TB and the trial showed no overall effect on mortality in patients with TB; it is possible that the dose used was insufficient. Clinical trial registered with www.controlled-trials.com/isrctn (ISRCTN35212132).

6 July 2010 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
SJS. P. Jørgensen
S. P. Jørgensen
JAJørgen Agnholt
Jørgen Agnholt
HGH. Glerup
H. Glerup
SLS. Lyhne
S. Lyhne
GVG. E. Villadsen
G. E. Villadsen
JDJ. F. Dahlerup
J. F. Dahlerup

1 February 2000 in Journal of Internal Medicine
Verified
Journal Article
Closed access
PDF file
HGH. Glerup
H. Glerup
KMK. Mikkelsen
K. Mikkelsen
LPL. Poulsen
L. Poulsen
EHE. Hass
E. Hass
SOS. Overbeck
S. Overbeck
EEE. F. Eriksen
E. F. Eriksen

1 September 2015 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
Tue Bjerg BennikeTue Bjerg Bennike
Tue Bjerg Bennike
TCThomas Gelsing Carlsen
Thomas Gelsing Carlsen
TPTorkell Ellingsen Professor
Torkell Ellingsen Professor
OBOle Kristian Bonderup
Ole Kristian Bonderup
HGHenning Glerup
Henning Glerup
VAVibeke Andersen
Vibeke Andersen
Background. The etiology of the inflammatory bowel diseases, including ulcerative colitis (UC), remains incompletely explained. We hypothesized that an analysis

1 November 2007 in The American Journal of Clinical Nutrition
Verified
Journal Article
Open access
PDF file
Christian WejseChristian Wejse
Christian Wejse
RORikke Olesen
Rikke Olesen
PRPaulo Rabna
Paulo Rabna
PKPernille Kaestel
Pernille Kaestel
PGPer Gustafson
Per Gustafson
MSMorten Sodemann
Morten Sodemann
Background: Little is known regarding vitamin D deficiency (VDD) in African populations and in tuberculosis (TB) patients. VDD has been shown to be associated with TB. Objective: We aimed to compare the degree of vitamin D insufficiency (VDI) and VDD in TB patients and healthy adult controls in a West African population. Design: An unmatched case-control study was performed at a Demographic Surveillance Site in Guinea-Bissau. Serum 25-hydroxyvitamin D3 [25(OH)D3] concentrations were measured in 362 TB patients and in 494 controls. Results: Hypovitaminosis D [25(OH)D3 ≤ 75 nmol/L] was more common in TB patients, but VDD [25(OH)D3 ≤ 50 nmol/L] was more common and more severe in controls. We observed hypovitaminosis D in 46% (167/362) of the TB patients and in 39% (193/494) of the controls; the relative risk (RR) of hypovitaminosis D was 1.18 (95% CI: 1.01, 1.38). VDD was observed in 8.5% (31/362) of the TB patients and in 13.2% (65/494) of the controls. The RR was 0.65 (95% CI: 0.43, 0.98), mainly because severe VDD [25(OH)D3 ≤ 25 nmol/L] was observed in only 1 of 362 TB patients (0.2%) and in 24 of 494 controls (4.9%). After adjustment for background factors, hypovitaminosis D was not more frequent in TB patients than in healthy controls, but the mean serum 25(OH)D3 concentration remained lower. Conclusions: Hypovitaminosis D was highly prevalent in TB patients and in healthy controls living at 12 °N; severe VDD was rare in TB patients. The finding indicates that the serum 25(OH)D3 concentration is associated with TB infection, but whether this role is a symptom or is causal was not established.